Clinical Trials in Phoenix

Showing 16061-16080 of 16,646 trials

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

NCT00821496

This study is desgigned to look at the effect of multiple dosing administration of VI-0521 on Oral Contraceptive medication.

Healthy

VIVUS LLC20 participantsStarted Jan 2009

Phoenix, Arizona, United States

COMPLETEDPhase 2< 1 mile

Memantine Therapy in Amyotrophic Lateral Sclerosis

NCT01020331

Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease progression correlates with possible changes in Tau in ALS patients based on ALS Functional Rating Scale (ALSFRS) scores.

Amyotrophic Lateral Sclerosis

Phoenix Neurological Associates, LTD20 participantsStarted Jun 2005

Phoenix, Arizona, United States

COMPLETEDPhase 3< 1 mile

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956

The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.

Fibromyalgia

Forest Laboratories321 participantsStarted Oct 2007

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +35 more locations

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

Memantine Therapy in Amyotrophic Lateral Sclerosis

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

Find Trials by Condition in Phoenix

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

BEYOND Pilot Study

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer